Metrion Biosciences
OverviewSuggest Edit
Metrion Biosciences is a contract research organization specializing in ion channel screening and drug development. It also offers a range of in vitro screening services that include cardiac safety and neurotoxicology testing and phenotypic assays.
| Type | Private | |
| Founded | 2015 | |
| HQ | Cambridge, GB | Map |
| Website | metrionbiosciences.com |
Latest Updates
| Employees (est.) (Nov 2021) | 24 | (+5%) |
Key People/Management at Metrion Biosciences
Keith McCullagh
Non-Executive Chairman
Marc Rogers
Founding Director and Chief Scientific Officer
Barry Kenny
Non-Executive Director
Mark Keogh
Non-Executive Director
Metrion Biosciences Office Locations
Metrion Biosciences has an office in Cambridge
Cambridge, GB (HQ)
Riverside 3, Suite 1, Granta Park, Great Abington
Metrion Biosciences Financials and Metrics
Summary Metrics
Founding Date | 2015 |
Metrion Biosciences total Funding | $4.9 m |
Metrion Biosciences latest funding size | $3.81 m |
Time since last funding | 8 months ago |
Metrion Biosciences investors | Innovate UK, Gresham House Ventures |
Metrion Biosciences's latest funding round in April 2021 was reported to be $3.8 m. In total, Metrion Biosciences has raised $4.9 m
Metrion Biosciences Online and Social Media Presence
331 Twitter followers
Metrion Biosciences has 331 Twitter Followers. The number of followers has increased 1.8% month over month and increased 2.7% quarter over quarter
Metrion Biosciences's Trends
Twitter Engagement Stats for @Metrion_Biosci
177
Tweets
129
Following
331
Followers
4
Tweets last 30 days
1.5
Avg. likes per Tweet
50%
Tweets with engagement
Metrion Biosciences News and Updates
February 01, 2021
Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences
TOKYO and CAMBRIDGE, England, Feb. 1, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) announces it will apply its world-leading structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new strategic collaboration with...
Metrion Biosciences Blogs
September 10, 2021
Alex’s Story So Far…
Written by Dr Alex Howarth Metrion Scientist Dr Alexander Howarth summarises below his undergraduate and postgraduate studies and how he came to join Metrion Biosciences. “In 2015, I graduated from the University of Sheffield with a BSc in Biomedical Sciences. The degree was fascinating and provided…
September 03, 2021
Pete’s Path into Electrophysiology
Written by Dr Peter Matthews Metrion Scientist Dr Peter Matthews summarises below his path into electrophysiology and recounts his experiences during his undergratuate and postgraduate studies and beyond. “I first became interested in the physiology and pharmacology of ion channels during my undergr…
July 26, 2021
Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development
Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development Appointment supports international growth within ion channel contract research and drug discovery Cambridge, UK, 26 July 2021: Metrion Biosciences Limited (“Metrion”), the specialist ion chan…
July 20, 2021
Discovery of KNa1.1 channel inhibitors – an account of Metrion’s first webinar
Metrion’s first “Ion channel drug discovery” webinar Metrion Biosciences’ inaugural ion channel webinar took place at the end of June and featured a presentation by Dr Jon Lippiat, from the School of Biomedical Sciences at the University of Leeds. Jon presented an inspiring and thought-provoking tal…
June 03, 2021
The Ionic Inspiration of Venomtech – by Steve Trim
Our guest blog, written by longstanding Friend and Collaborator Steve Trim, CSO and Founder of Venomtech is presented below. An early career at Pfizer, Sandwich “Why spider man is joining forces with ion man” is a newspaper headline I’ll never forget, and one of the few puns about my work that I rea…
April 19, 2021
Metrion Biosciences Appoints Mark Keogh as Non-Executive Director
Metrion Biosciences appoints Mark Keogh as Non-Executive Director Appointment strengthens the financial and corporate experience of Metrion’s Board in support of the Company’s planned international growth Cambridge, UK, 19 April 2021: Metrion Biosciences Limited (“Metrion”), the specialist ion chann…
Metrion Biosciences Frequently Asked Questions
When was Metrion Biosciences founded?
Metrion Biosciences was founded in 2015.
Who are Metrion Biosciences key executives?
Metrion Biosciences's key executives are Keith McCullagh, Marc Rogers and Barry Kenny.
How many employees does Metrion Biosciences have?
Metrion Biosciences has 24 employees.
Who are Metrion Biosciences competitors?
Competitors of Metrion Biosciences include Parsolex, Selvita and Selcia.
Where is Metrion Biosciences headquarters?
Metrion Biosciences headquarters is located at Riverside 3, Suite 1, Granta Park, Great Abington, Cambridge.
Where are Metrion Biosciences offices?
Metrion Biosciences has an office in Cambridge.
How many offices does Metrion Biosciences have?
Metrion Biosciences has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies